Who are RVNC's key supply-chain partners?

Map Revance (RVNC)'s suppliers, customers, dependencies, and concentration risk.

What is RVNC's biggest supplier?

See Revance (RVNC) top suppliers, their share of cost of goods sold, and geographic concentration risk.

See Revance (RVNC) top customers, share of revenue, and end-market concentration risk.

$3.65

Last traded 2025-02-06 — delisted

NASDAQ · Healthcare · Biotechnology · $381.0M mcap · 91M float · 3.24% daily turnover

1 relationships

As Filer

counterparties named

As Counterparty

mentioned by others

2025-01-21

Earliest Filing

2025-01-21

Latest Filing

1 mentions

Other companies that named RVNC in their SEC 8-K filings.

Filed By	Relationship	Summary	Filing Date	SEC
DRMAW Dermata Therapeutics, Inc.	partner	Entered into a Clinical Trial Collaboration Agreement to conduct a multi-center trial evaluating Xyngari and Daxxify.	2025-01-21	View

Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR